IgA Nephropathy
Advertisement
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.
An analysis Identified SIRT1, BAG3, COKN1A and FOS as potential autophagy-related biomarkers for IgAN.
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy to help with risk stratification.
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.
We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).
A systematic evaluation compared the incidence of IgAN and changes in its pathology before and during the COVID-19 pandemic.
Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.
A teen who presented with nephrotic syndrome was diagnosed with both dense deposit disease and IgA nephropathy.
Researchers reported the progression of kidney function throughout the course of IgA nephropathy.
Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks?
Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
Zigakibart for treatment of IgA nephropathy (IgAN) was well tolerated, reduced proteinuria, and stabilized eGFR at 76 weeks.
Researchers reported data from APPLAUSE-IgAN assessing the effects of iptacopan on proteinuria at nine months.
A study examined the clinical relevance of urinary mRNA levels in patients with IgA nephropathy (IgAN).
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.